middle.news
Mesoblast’s RYONCIL Surges with FDA Nod and $30M Quarterly Revenue
9:59am on Tuesday 25th of November, 2025 AEDT
•
Healthcare
Read Story
Mesoblast’s RYONCIL Surges with FDA Nod and $30M Quarterly Revenue
9:59am on Tuesday 25th of November, 2025 AEDT
Key Points
FDA approval and commercial launch of RYONCIL in December 2024
Q1 FY26 RYONCIL gross revenue reached US$22 million, with Q2 forecast above US$30 million
Ongoing Phase 3 trials for chronic low back pain and chronic heart failure
Strategic U.S. manufacturing scale-up to improve cost efficiency and capacity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MSB
OPEN ARTICLE